3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Classical hematology
4
Conditions
Hemophilia A
4
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
Cytarabine
9
Dalteparin
8
Rivaroxaban
7
Daunorubicin
7
apixaban
6
Etoposide
6
Methotrexate
5
Idarubicin
5
Heparin, Low-Molecular-Weight
5
Cyclophosphamide
5
emicizumab
4
Tinzaparin
4
Thioguanine
4
Mitoxantrone
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Enoxaparin
4
pegfilgrastim
3
hetrombopag
3
epoetin beta
3
Saline Solution
3
Radiotherapy
3
Hydrocortisone
3
Erythropoietin
3
Dexamethasone
3
Aspirin
3
Asparaginase
3
telapristone acetate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
emicizumab
×
Classical hematology
×
Clear all
NCT03020160
2023-01-11
HAVEN 4
Hoffmann-La Roche
Phase 3
Completed
48 enrolled
44 charts
1 FDA
NCT02847637
2022-11-16
HAVEN 3
Hoffmann-La Roche
Phase 3
Completed
152 enrolled
46 charts
1 FDA
NCT02622321
2021-06-24
HAVEN 1
Hoffmann-La Roche
Phase 3
Completed
113 enrolled
45 charts
1 FDA
NCT02795767
2021-06-02
HAVEN 2
Hoffmann-La Roche
Phase 3
Completed
88 enrolled
65 charts
1 FDA